News ReleaseView printer-friendly version << Back
Pacira Pharmaceuticals and Nuance Biotech Announce License Agreement for EXPAREL® in China
“We are thrilled to expand the commercial opportunity for EXPAREL to
“EXPAREL is an ideal fit for the Nuance portfolio given our focus on developing and commercializing innovative products for the Chinese market,” stated
Under the terms of the agreement, Pacira has granted Nuance the exclusive rights to develop and commercialize EXPAREL in
EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. The product combines bupivacaine with DepoFoam®, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation. If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine. EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.
Nuance Biotech is a leading
The company was established in 2014 and has rapidly built a unique portfolio that includes several leading brands. The portfolio includes a series of products which are currently commercialized, in registration and an impressive portfolio currently in clinical development. Nuance has both a specialty TA focus as well as targeting surgery departments across leading hospitals in
Led by a team of seasoned
Company Contacts: Pacira Investor Contact:
Susan Mesco(973) 451-4030 email@example.com Christian Pedetti (973) 254-4387 Christian.Pedetti@pacira.com Pacira Media Contact: Coyne Public Relations Alyssa Schneider(973) 588-2270 firstname.lastname@example.org